My work in breast cancer spans the spectrum from public policy issues to basic science and the impact of both on the delivery of clinical care. In addition to being the Director of the Breast Care Center and the Clinical Leader of the NCI-designated Breast Oncology Program, I direct (as Principal Investigator) two large multicenter collaborations in my areas of interest. The I-SPY TRIAL (Investigating Serial Studies to Predict Your Therapeutic Response using Imaging And molecular analysis) is a correlative science study for women with stage II/III breast cancer receiving neoadjuvant chemotherapy, where women receive serial magnetic resonance imaging (MRI) and core biopsies during the course of their therapy. This role led to the development of the I-SPY 2 Trial (PI), a large-scale trial that involves a unique collaboration by scientists from the NCI, the FDA, and nearly 20 major cancer research centers across the country. A distinctive feature of the trial is that it will screen multiple drugs from multiple companies—up to 12 different cancer drugs over the course of the trial. I-SPY 2 has the potential to significantly reduce the cost of drug development and speed the process of screening drugs with the goal of bringing safe and effective new drugs to market more efficiently. We are developing tools to tailor treatment for fast and slow growing tumors.
My role as former PI of the Biomarker Discovery Laboratory for the Early Detection Research Network (EDRN) led to the development of the ATHENA Breast Health Network, an integrated breast health network across the University of California campuses and the Sanford Medical Center. In this ambitious project, we are recruiting 150,000 women who are undergoing screening, and will follow them through any biopsy, diagnosis, treatment, and follow-up. Importantly, this effort will serve to create an engine to provide and improve breast cancer prevention services.